Vyne Therapeutics’ attempt to develop a safer, more tolerable BET inhibitor has hit turbulence. | Vyne Therapeutics’ attempt ...

No association was observed between serious infection risk and Janus kinase inhibitor use in patients with immune-mediated inflammatory skin disease.

NS-229 is an investigational selective Janus kinase 1 inhibitor designed to prevent tissue damage caused by EGPA by suppressing immune cell activation.

Janus kinase (JAK) inhibitors are associated with an increased risk for lung cancer but not overall cancer among older patients in the United States with rheumatoid arthritis (RA), according to study ...

Only half of patients showed clinical improvement attributed to the medication, but only one new complication occurred.

Panelists discuss how treatment selection among Janus kinase (JAK) inhibitors for myelofibrosis involves considering specific ...

In addition to a greater risk for serious infection, patients with atopic dermatitis initiating JAK inhibitors vs Th2 cytokine inhibitors had a greater risk of Candida infections and a slightly ...

Roivant Sciences secures $5.2B for advancing late-stage drugs like IMVT-1402 & brepocitinib. Click here to read an analysis ...

Currently approved therapies for alopecia areata are all JAK inhibitors and carry boxed warning labels, King noted. Bempikibart simultaneously inhibits the IL-7 receptor, which "rebalances" T ...

A prospective registry study found a greater risk for infections associated with JAK inhibitors in adolescents and adults with moderate to severe atopic dermatitis compared with biologics.

IL-17 inhibitors, at this moment, they inhibit IL-17A, which is a specific inflammatory molecule. And thirdly, Janus kinase inhibitors, the one that's on the market for ankylosing spondylitis ...